| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Surojeet Sengupta, Rachel Schiff, Benita S Katzenellenboge. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast cancer research and treatment. vol 117. issue 2. 2009-11-17. PMID:18807177. |
pi3k/akt and mapk pathways are known to result in the phosphorylation and functional inactivation of tuberin (tsc2) of tuberous sclerosis complex thereby negating its inhibitory effects on mtor, which in turn stimulates the translational machinery. |
2009-11-17 |
2023-08-12 |
Not clear |
| Hui H Zhang, Jingxiang Huang, Katrin Düvel, Bernard Boback, Shulin Wu, Rachel M Squillace, Chin-Lee Wu, Brendan D Mannin. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PloS one. vol 4. issue 7. 2009-11-10. PMID:19593385. |
one direct substrate that is inhibited by akt-mediated phosphorylation is the tuberous sclerosis complex 2 (tsc2) protein, which associates with tsc1 and acts as a critical negative regulator of the mammalian target of rapamycin (mtor) complex 1 (mtorc1). |
2009-11-10 |
2023-08-12 |
Not clear |
| Lisa R Young, David N Franz, Preeti Nagarkatte, Christopher D M Fletcher, Kathryn A Wikenheiser-Brokamp, Matthew D Galsky, Thomas C Corbridge, Anna P Lam, Michael J Gelfand, Francis X McCormac. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. vol 136. issue 3. 2009-10-08. PMID:19349386. |
mutations in tuberous sclerosis complex (tsc) genes are associated with dysregulated mammalian target of rapamycin (mtor)/akt signaling and unusual neoplasms called perivascular epithelioid cell tumors (pecomas), including angiomyolipomas (amls) and lymphangioleiomyomatosis (lam). |
2009-10-08 |
2023-08-12 |
Not clear |
| Bobby Bhatia, Paul A Northcott, Dolores Hambardzumyan, Baskaran Govindarajan, Daniel J Brat, Jack L Arbiser, Eric C Holland, Michael D Taylor, Anna Marie Kenne. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer research. vol 69. issue 18. 2009-10-07. PMID:19738049. |
one of the consequences of igf signaling is inactivation of the mammalian target of rapamycin (mtor)-suppressing tuberous sclerosis complex (tsc), comprised of tsc1 and tsc2, leading to increased mrna translation. |
2009-10-07 |
2023-08-12 |
mouse |
| Peter B Crin. Focal brain malformations: seizures, signaling, sequencing. Epilepsia. vol 50 Suppl 9. 2009-09-29. PMID:19761448. |
focal cortical dysplasias, hemimegalencephaly, and tubers in tuberous sclerosis complex all exhibit evidence for hyperactive mtor signaling, suggesting that these disorders form a spectrum of malformations or "toropathies" characterized by disorganized cortical lamination, cytomegaly, and intractable seizures. |
2009-09-29 |
2023-08-12 |
Not clear |
| Ruifang Mi, Jianhui Ma, Dechang Zhang, Limin Li, Hongbing Zhan. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. Journal of genetics and genomics = Yi chuan xue bao. vol 36. issue 6. 2009-08-13. PMID:19539245. |
efficacy of combined inhibition of mtor and erk/mapk pathways in treating a tuberous sclerosis complex cell model. |
2009-08-13 |
2023-08-12 |
mouse |
| Cleo S Bonnet, Mark Aldred, Christopher von Ruhland, Rebecca Harris, Richard Sandford, Jeremy P Cheadl. Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Human molecular genetics. vol 18. issue 12. 2009-07-08. PMID:19321600. |
clinical trials are underway for the treatment of tuberous sclerosis (tsc)-associated tumours using mtor inhibitors. |
2009-07-08 |
2023-08-12 |
mouse |
| Ling-Hui Zeng, Nicholas R Rensing, Michael Won. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 21. 2009-06-23. PMID:19474323. |
we recently found that the mammalian target of rapamycin (mtor) signaling pathway is involved in epileptogenesis, and mtor inhibitors prevent epilepsy in a mouse model of tuberous sclerosis complex. |
2009-06-23 |
2023-08-12 |
mouse |
| Marco Chilosi, Maurizio Pea, Guido Martignoni, Matteo Brunelli, Stefano Gobbo, Venerino Poletti, Franco Bonett. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 22. issue 2. 2009-04-30. PMID:19060845. |
the pathogenesis of lymphangioleiomyomatosis is determined by mutations affecting tuberous sclerosis complex (tsc) genes, with eventual deregulation of the rheb/mtor/p70s6k pathway, and the potential therapeutic activity of mtor inhibitors is currently under investigation. |
2009-04-30 |
2023-08-12 |
Not clear |
| Mitsunori Miyazaki, Karyn A Esse. REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch. American journal of physiology. Cell physiology. vol 296. issue 3. 2009-04-27. PMID:19129461. |
knock down of tuberous sclerosis complex 2 (tsc2) using small interfering (si)rna potently activated mtor signaling and was sufficient to rescue redd2 inhibition of mtor activity, suggesting that redd2 functions by modulating tsc2 function. |
2009-04-27 |
2023-08-12 |
Not clear |
| Katarzyna Kotulska, Magdalena Larysz-Brysz, Wieslława Grajkowska, Jarosław Jóźwiak, Paweł Włodarski, Mustafa Sahin, Joanna Lewin-Kowalik, Dorota Domańska-Pakieła, Sergiusz Jóźwia. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. vol 12. issue 2. 2009-04-24. PMID:17990907. |
cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mtor pathway abnormalities. |
2009-04-24 |
2023-08-12 |
Not clear |
| Jaroslaw Jozwiak, Katarzyna Kotulska, Magdalena Lojek, Ryszard Galus, Sergiusz Jozwiak, Dariusz Polnik, Pawel K Wlodarsk. Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway. The American Journal of dermatopathology. vol 31. issue 1. 2009-03-18. PMID:19155728. |
fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mtor pathway. |
2009-03-18 |
2023-08-12 |
Not clear |
| Christopher B Marshall, Jason Ho, Claudia Buerger, Michael J Plevin, Guang-Yao Li, Zhihong Li, Mitsuhiko Ikura, Vuk Stamboli. Characterization of the intrinsic and TSC2-GAP-regulated GTPase activity of Rheb by real-time NMR. Science signaling. vol 2. issue 55. 2009-03-18. PMID:19176517. |
tuberous sclerosis complex 2 (tsc2), whose gene is frequently mutated in tuberous sclerosis, increases the guanosine triphosphatase (gtpase) activity of the small heterotrimeric gtp-binding protein (g protein) rheb, thus resulting in the decreased activity of the mammalian target of rapamycin (mtor), the master regulator of cell growth. |
2009-03-18 |
2023-08-12 |
Not clear |
| Julian R Sampso. Therapeutic targeting of mTOR in tuberous sclerosis. Biochemical Society transactions. vol 37. issue Pt 1. 2009-02-11. PMID:19143643. |
therapeutic targeting of mtor in tuberous sclerosis. |
2009-02-11 |
2023-08-12 |
mouse |
| Julian R Sampso. Therapeutic targeting of mTOR in tuberous sclerosis. Biochemical Society transactions. vol 37. issue Pt 1. 2009-02-11. PMID:19143643. |
failure in the regulation of mtor (mammalian target of rapamycin) appears to be critical to the pathogenesis of the inherited disorder tuberous sclerosis and the related lung disease lam (lymphangioleiomyomatosis). |
2009-02-11 |
2023-08-12 |
mouse |
| Julian R Sampso. Therapeutic targeting of mTOR in tuberous sclerosis. Biochemical Society transactions. vol 37. issue Pt 1. 2009-02-11. PMID:19143643. |
both diseases are caused by mutations of tsc1 or tsc2 (tsc is tuberous sclerosis complex) that impair gap (gtpase-activating protein) activity of the tsc1-tsc2 complex for rheb, leading to inappropriate activity of signalling downstream of mtorc1 (mtor complex 1). |
2009-02-11 |
2023-08-12 |
mouse |
| Valerio Napolioni, Romina Moavero, Paolo Curatol. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain & development. vol 31. issue 2. 2009-02-09. PMID:19028034. |
tuberous sclerosis complex (tsc) is a multisystem genetic disorder with variable phenotypic expression, due to a mutation in one of the two genes, tsc1 and tsc2, and a subsequent hyperactivation of the downstream mtor pathway, resulting in increased cell growth and proliferation. |
2009-02-09 |
2023-08-12 |
Not clear |
| Jeremy Marsh, Purna Mukherjee, Thomas N Seyfrie. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 14. issue 23. 2009-02-05. PMID:19047102. |
many astrocytomas are also tuberous sclerosis complex 2 (tsc2) protein deficient and exhibit constitutive mammalian target of rapamycin (mtor) activity. |
2009-02-05 |
2023-08-12 |
mouse |
| Kevin Kyungsuk Park, Kai Liu, Yang Hu, Patrice D Smith, Chen Wang, Bin Cai, Bengang Xu, Lauren Connolly, Ioannis Kramvis, Mustafa Sahin, Zhigang H. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science (New York, N.Y.). vol 322. issue 5903. 2008-12-04. PMID:18988856. |
reactivating this pathway by conditional knockout of tuberous sclerosis complex 1, another negative regulator of the mtor pathway, also leads to axon regeneration. |
2008-12-04 |
2023-08-12 |
mouse |
| Anne M Pruznak, Abid A Kazi, Robert A Frost, Thomas C Vary, Charles H Lan. Activation of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-beta-D-ribonucleoside prevents leucine-stimulated protein synthesis in rat skeletal muscle. The Journal of nutrition. vol 138. issue 10. 2008-12-02. PMID:18806097. |
this ability of aicar to produce muscle leucine resistance could not be attributed to a change in phosphorylation of tuberous sclerosis complex (tsc)2, the formation of a tsc1.tsc2 complex, the binding of raptor with mtor, or the phosphorylation of eukaryotic elongation factor-2. |
2008-12-02 |
2023-08-12 |
rat |